干性年龄相关性黄斑变性的治疗:治疗途径、临床试验与未来方向
干性年龄相关性黄斑变性(AMD)目前尚无抗VEGF那样的标准治疗。本综述汇总了截至发表时的干预性临床试验,涵盖抗氧化药物、补体级联抑制剂、神经保护剂、视觉周期抑制剂、基因治疗和细胞治疗六大方向,部分早期临床试验结果令人鼓舞,更多试验正在进行中。
要点
- 干性AMD治疗探索包括抗氧化、补体抑制、神经保护、视觉周期抑制、基因治疗和细胞治疗六大途径。
- 部分早期临床试验已提供有希望的结果,但尚无获批的标准治疗。
- 抗VEGF治疗改变了新生血管性AMD的预后,干性AMD尚未见到类似突破。
核心结论
- 干性AMD有多种靶点的治疗途径正在研究中,部分早期临床试验结果令人鼓舞,更多试验正在进行或即将开展。
研究设计与样本
- 本文为综述,旨在更新截至发表时的干性AMD干预性临床试验及未来前景。
主要发现
- 减少疾病进展速度的探索途径包括抗氧化药物、补体级联抑制剂、神经保护剂、视觉周期抑制剂、基因治疗和细胞治疗。
- 部分早期临床试验已提供有希望的结果。
临床怎么用
- 眼科医生可了解干性AMD六大治疗途径的临床试验进展,但目前尚无获批的标准治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The identification of the central role of vascular endothelial growth factor (VEGF) in the pathogenesis of neovascular AMD and the introduction of anti-VEGF agents as gold-standard treatment, have drastically changed its prognosis-something yet to be seen in dry AMD. Several therapeutic avenues with a wide variability of targets are currently being investigated in dry AMD. The approaches being investigated to reduce the rate of disease progression include, (1) drugs with antioxidative properties, (2) inhibitors of the complement cascade, (3) neuroprotective agents, (4) visual cycle inhibitors, (5) gene therapy and (6) cell-based therapies. A number of early phase clinical trials have provided promising results, with many more ongoing and anticipated in the near future. In this review, we aim to provide an update of the interventional trials to date and future prospects for the treatment of dry AMD.
引用
- Cabral de Guimaraes TA, Daich Varela M, Georgiou M, et al. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol. 2021. PMID: 33741584. doi:10.1136/bjophthalmol-2020-318452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。